Summary of Upcoming IPOs - A total of 4 companies are scheduled for IPO review from August 4 to August 8, aiming to raise a combined total of 1.912 billion yuan [1][2]. Company Details Zhongcheng Consulting - Planned fundraising was reduced from 330 million yuan to 200 million yuan, with the removal of EPC business expansion and liquidity support projects [3][13]. - The company specializes in engineering cost consulting, bidding agency, project supervision, and management services [13][14]. Fengbei Biological - The fundraising target was cut from 1 billion yuan to 750 million yuan, eliminating liquidity support projects [7][18]. - The company focuses on the comprehensive utilization of waste oil resources, producing bio-based materials and biofuels [18][19]. Jieke Co., Ltd. - The planned fundraising decreased from 750 million yuan to 676 million yuan, with adjustments made to the funding for the intelligent robot production project and the removal of liquidity support [10][23]. - The company is engaged in the research, production, and sales of collaborative robot products, with applications in various high-tech fields [23][24]. Nante Technology - The fundraising target was reduced from 420 million yuan to 286 million yuan, with the removal of certain expansion projects and adjustments to funding for other projects [12][27]. - The company specializes in the research, production, and sales of precision mechanical components [27][28]. Financial Performance Overview - Zhongcheng Consulting reported total assets of approximately 602.75 million yuan and a net profit of 105.39 million yuan for the year ending December 31, 2024 [17]. - Fengbei Biological's total assets reached approximately 1.236 billion yuan, with a net profit of 123.82 million yuan for the same period [21]. - Jieke Co., Ltd. reported total assets of approximately 104.67 million yuan and a net profit of 622,800 yuan for the year ending December 31, 2024 [25]. - Nante Technology's total assets were approximately 1.417 billion yuan, with a net profit of 98.22 million yuan for the same period [29]. Fundraising Projects Zhongcheng Consulting - Major projects include engineering consulting service network construction and R&D and information technology projects, with a total investment of 1.299 billion yuan [18]. Fengbei Biological - Key projects include the construction of a facility for producing 300,000 tons of oleic acid methyl ester and other bio-based products, with a total investment of 1.04 billion yuan [22]. Jieke Co., Ltd. - The company plans to invest in projects related to the production of collaborative robots and R&D center construction, with a total investment of approximately 754.31 million yuan [26]. Nante Technology - The company is focusing on precision component production and expansion projects, with a total investment of approximately 501.42 million yuan [31].

Core Viewpoint - The company, Jieka Robotics, is facing challenges in its IPO process and financial performance, despite being positioned in a growing market for collaborative robots. The company has reported a slowdown in revenue growth and has experienced fluctuations in profitability, raising concerns about its future prospects and the viability of its expansion plans [1][3][5]. Revenue Growth - Jieka Robotics has shown revenue growth from 281 million yuan in 2022 to 400 million yuan in 2024, with a compound annual growth rate (CAGR) of 19.42% during the reporting period, significantly lower than the 141.16% CAGR from 2020 to 2022 [6][7]. - The company's main revenue source is collaborative robot systems, which accounted for 93.63% of total revenue in 2024, up from 77.24% in 2022 [9][10]. - The projected revenue for 2024 was initially estimated at 555 million yuan, indicating that actual performance has not met expectations [7]. Profitability Concerns - Jieka Robotics reported a net profit of 622,800 yuan in 2024, recovering from a loss of 2.85 million yuan in 2023, but the net profit has shown significant volatility [12][13]. - The company has accumulated undistributed losses of 58.03 million yuan as of the reporting period, indicating ongoing financial challenges [12][14]. - The increase in research and sales expenses has impacted short-term profitability, with R&D expenses rising to 19.21% of total revenue in 2024 [15][16]. Expansion Plans and Market Position - Jieka Robotics plans to raise 700 million yuan through its IPO, with 370 million yuan allocated for an intelligent robot production project aimed at achieving an annual production capacity of 40,000 units [19][20]. - The global market for collaborative robots is expected to grow significantly, with projections of 287,400 units sold by 2028, but the company acknowledges its current market position is not competitive with leading brands [18][19]. - The company has a production capacity of 8,000 units for collaborative robots in 2024, which is only one-fifth of its long-term target, raising questions about its ability to utilize new capacity effectively [21][23].

文/梧桐晓编 自智翔金泰（688443）2023年6月20日上市以后，A股未再有亏损企业实现IPO上市。2024年下半年以来，各界要求恢复优质未盈利企业IPO上市的呼声持续增 长。监管系统领导也在不同场合表态支持优质未盈利科技企业发行上市。2025年3月11日，中国证监会党委召开扩大会议，深入学习习近平总书记在全国两会期 间的重要讲话精神和全国两会精神，研究部署资本市场贯彻落实具体举措。会议指出： 证监会要在支持科技创新和新质生产力发展上持续加力。增强制度包容 性、适应性，支持优质未盈利科技企业发行上市，稳妥恢复科创板第五套标准适用，尽快推出具有示范意义的典型案例，更好促进科技创新和产业创新融合发 展。 综观目前200家IPO在审企业，只有9家是报告期最近一年未盈利的，其中申报科创板的8家，申报北交所的1家。 9家在审未盈利IPO企业基本信息 单位：万元 | 公司简称 | 拟上市板 块 | 最近一年 营收 | 最近一年 净利润 | 上市标准 | 审核状态 | 保存机构 | 受理日期 | | --- | --- | --- | --- | --- | --- | --- | --- | | 西安奕材 | 科创板 ...